ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

Planchard, D.*; Janne, P. A.; Cheng, Y.; Yang, J. C. -H.; Yanagitani, N.; Kim, S-W; Sugawara, S.; Yu, Y.; Fan, Y.; Geater, S. L.; Laktionov, K.; Lee, C. K.; Valdiviezo, N.; Ahmed, S.; Maurel, J-M; Andrasina, I; Goldman, J.; Ghiorghiu, D.; Rukazenkov, Y.; Todd, A.; Kobayashi, K.哈尔滨医科大学
New England Journal of Medicine2023-11-23DOI: 10.1056/NEJMoa2306434
8被引10阅读
引用收藏
分享

摘要

BackgroundOsimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy.MethodsIn this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed.ResultsA total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib-chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy - a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents.ConclusionsFirst-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC.

学科与关键词

关键词
CELL LUNG-CANCERPLATINUMCOMBINATIONGEFITINIBSURVIVAL
相关
加载中…
  • Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
    Janne, P.; Planchard, D.; Cheng, Y.; Yang, J. C. -H.; Yanagitani, N.; Kim, S. -W.; Sugawara, S.; Yu, Y.; Fan, Y.; Geater, S. L.; Laktionov, K.; Lee, C. K.; Valdivieso, N.; Ahmed, S.; Maurel, J. -M.; Andrasina, I.; Goldman, J.; Ghiorghiu, D.; Kulkarni, D.; Huang, X.; Kobayashi, K.被引 1
  • First-line (1L) osimertinib (osi) &plusmn; platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
    Cheng, Y.; Yu, Y.; Fan, Y.; Jiang, L.; Wu, L.; Hu, J.; Wang, J.; Yao, W.; Han, Z.; Yao, Y.; Fang, J.; Sun, M.; Wang, Q.; Pan, Y.; Wu, R.; Liu, J.; Liu, Y.; Kulkarni, D.; Huang, X.; Janne, P. A.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
  • Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
    Lv, Chao; Fang, Wentao; Wu, Nan; Jiao, Wenjie; Xu, Shidong; Ma, Haitao; Wang, Jia; Wang, Rui; Ji, Chunyu; Li, Shaolei; Wang, Yuzhao; Yan, Shi; Lu, Fangliang; Pei, Yuquan; Liu, Yinan; Yang, Yue*Lung Cancer, 2023, 178: 151-156.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
New England Journal of Medicine
发表日期
2023-11-23
卷期
第 389 卷, 第 21 期
页码
1935-1948
DOI
10.1056/NEJMoa2306434
语言
ENGLISH
期刊等级
Q1
成果收录
SCIE
资助标注
We thank all the patients and their families; all the trial-site coordinators; the AstraZeneca trial team (Xiangning Huang, Ph.D., Dakshayini Kulkarni, Ph.D., Elena Armenteros Monterroso, Ph.D., and Neha P. Amin, M.D.); and Hedley Coppock, Ph.D., of Ashfie

作者

  • P

    Planchard, D. (通讯) (第一作者)

  • J

    Janne, P. A.

查看全部 21 位作者收起作者
  • C

    Cheng, Y.

  • Y

    Yang, J. C. -H.

  • Y

    Yanagitani, N.

    canc inst hosp

  • K

    Kim, S-W

  • S

    Sugawara, S.

  • Y

    Yu, Y.

    harbin med univ

  • F

    Fan, Y.

    zhejiang canc hosp

  • G

    Geater, S. L.

  • L

    Laktionov, K.

  • L

    Lee, C. K.

  • V

    Valdiviezo, N.

  • A

    Ahmed, S.

  • M

    Maurel, J-M

  • A

    Andrasina, I

  • G

    Goldman, J.

  • G

    Ghiorghiu, D.

  • R

    Rukazenkov, Y.

  • T

    Todd, A.

  • K

    Kobayashi, K.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417